Cytel

MAY 14, 2024

Written by Angela Vinken and Patti Arsenault Key Opinion Leaders (KOLs) — i.e., trusted, well-respected experts — are crucial in clinical research, especially in rare diseases. The challenge, however, is how to use KOLs wisely — they are often clinicians first and researchers second, and their time is in high demand.

Clinical Trials 59

Clinical Trials Disease Trials Clinical Research 59

Drug Target Review

MAY 7, 2024

Why are biomarkers particularly critical in the context of rare diseases? Developing novel therapeutic approaches for rare diseases poses inherent challenges due to the limited populations available for testing. How do AI-enhanced approaches accelerate the drug development process for rare diseases?

Disease 59

Disease Clinical Trials Clinical Pharmacology Trials 59

The Pharma Data

SEPTEMBER 29, 2021

to enhance outcomes, new treatments which will target kidney-specific disease mechanisms are highly desired,” said Hiddo L. Christian Rommel, Member of the chief Committee of Bayer AG’s Pharmaceutical Division and Head of Research and Development. 1 in 3 adults is at risk for the disease. In the U.S.,

Clinical Development 52

Clinical Development Disease Clinical Trials Trials 52

Drug Discovery World

DECEMBER 7, 2022

If clinical research into collagen maintains this momentum, we can expect to see innovations in wound healing and bone care making their way to patients in the coming years.”. billion by 2028. The collagen trials fell into five main categories: skin disease, wound care, bone disease, osteoarthritis, and rheumatoid arthritis. “As

Clinical Trials 130

Clinical Trials Trials Clinical Research Clinical Development 130

Drug Discovery World

MAY 29, 2024

All 11 trial participants had experienced disease progression in prior immunotherapy treatment before joining the trial. These preliminary findings represent some of the initial positive evidence emerging from the burgeoning field of clinical research on cancer therapies leveraging gut microbiota.

Trials 130

Trials Clinical Trials Treatment Clinical Development 130

Labcorp Drug Development

MARCH 7, 2023

The field of nephrology clinical research has been steadily adding new interventional trials over the last five years at an average pace of 176 trials per year. This activity reflects the … The post Enabling better access to kidney disease trials appeared first on Insights From Our Labs to Yours.

Trials 52

Trials Disease Clinical Research Research 52

Drug Discovery World

APRIL 25, 2023

“We have reached an important milestone with the dosing of the second participant in our clinical trial evaluating a potentially groundbreaking CAR-T cell therapy to cure HIV,” said Mehrdad Abedi, Professor of Internal Medicine, Hematology and Oncology and co-investigator of the study. “So

Research 130

Research Clinical Trials Therapies Clinical Development 130

Drug Discovery World

FEBRUARY 10, 2023

The top stories: Study shines a light on representation in clinical research A diversity study has shown that clinical trials should use real world diseases epidemiology data, rather than US Census Bureau race and ethnicity data, to ensure enrolment reflects the populations affected by different diseases.

Clinical Trials 130

Clinical Trials Trials Drugs Vaccine 130

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

Cytel

NOVEMBER 29, 2022

Bayesian methods have continuously played a key role in transforming clinical research in therapeutic areas such as oncology and rare diseases, and in addressing clinical development challenges for COVID-19 drugs, devices, and biologics.

Clinical Trials 52

Clinical Trials Trials Clinical Development Clinical Research 52

Drug Target Review

SEPTEMBER 5, 2024

I am a pharmacist by training and continued with a PhD in Clinical Pharmacology. However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company.

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

Drug Discovery World

MARCH 5, 2024

We now commonly refer to epilepsy as ‘epilepsies’, with the recognition that it isn’t a singular disease. Here, we are building on learnings from other epilepsies where tissue is available as well as genetics to help understand universal disease mechanisms across epilepsies.

Disease 147

Disease Treatment Research Pharmaceutical Companies 147

Drug Discovery World

FEBRUARY 10, 2023

The research will support the clinical development of CTx001, CTx’s lead gene therapy asset for the treatment of GA, by enabling the identification of patients with complement-driven AMD for future interventional studies.

Clinical Development 130

Clinical Development Therapies Disease Treatment 130

Drug Discovery World

FEBRUARY 12, 2024

In 2024, we can expect another wave of innovative new drugs to be developed using the technology, given that the AI-fuelled small molecule discovery pipeline is growing by almost 40% annually.” The challenge is harnessing the power of AI within a highly regulated industry.

Small Molecule 349

Small Molecule Regulations Clinical Trials Therapies 349

Conversations in Drug Development Trends

FEBRUARY 22, 2023

Rare Disease Day on February 28th is a chance for rare disease communities to come together as one and join in conversation with stakeholders searching for treatments, raising money to support research, and changing the way healthcare and governments interact with patients. In my case, my daughter Iris has GM1 gangliosidosis.

Disease 52

Disease Clinical Trials Trials Treatment 52

Vial

MARCH 1, 2024

By type of service, clinical research services accounted for the lion’s share of the North American CRO services market, followed by early-phase development services, laboratory services, and consulting services. This acquisition has allowed the company to position itself as a global leader in clinical research services.

Clinical Trials 52

Clinical Trials Clinical Research Laboratories Trials 52

The Pharma Data

JANUARY 25, 2021

“The establishment of an Advisory Board focusing on Alzheimer’s disease, and the recruitment of such an impressive group of scientific and clinical leaders in this field is an extremely important step forward for the Company,” stated Paul Brennan, NervGen’s President & CEO. Dr.

Disease 40

Disease Clinical Development Molecular Biology Treatment 40

Conversations in Drug Development Trends

FEBRUARY 6, 2023

At Worldwide, this topic arises frequently in discussion with rare disease sponsors. As genome-wide association studies to identify genetic markers for common diseases increase, these questions will surface even more. Guidance in this area is much needed. Read the full article!

Clinical Trials 52

Clinical Trials Trials Disease Clinical Development 52

Vial

MARCH 25, 2024

Therapeutic Area Coverage Worldwide Clinical Trials (Worldwide) focuses on the following therapeutic areas: neuroscience, oncology , rare diseases, and cardiometabolic and inflammatory diseases. In common with Worldwide, Vial therapeutic areas include oncology , neurology , cardiology , and rare diseases.

Clinical Trials 52

Clinical Trials Trials Clinical Development Clinical Research 52

Vial

APRIL 10, 2024

The strong commitment to innovation allows IQVIA to provide advanced analytics, technology solutions, and industry-specific expertise in the health information technologies and clinical research domains. IQVIA has a vast collection of healthcare information, including over 1.2 increase on a reported basis and an 4.8%

Clinical Trials 52

Clinical Trials Trials Compliance Clinical Research 52

Drug Target Review

FEBRUARY 29, 2024

During my academic career, I had the opportunity to examine the underlying causes of neurodegenerative diseases like Parkinson’s disease and develop novel animal models to investigate potential disease-modifying therapeutics. For instance, we know ageing is a primary risk factor for many neurodegenerative diseases.

Therapies 111

Therapies Disease Clinical Trials Science 111

The Pharma Data

APRIL 8, 2021

Since its first approval in renal cell carcinoma nearly two years ago, KEYTRUDA has become an important first-line treatment option in combination with axitinib for patients with advanced renal cell carcinoma,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Disease 52

Disease Therapies Research Laboratories Treatment 52

Precision for Medicine

APRIL 7, 2023

Our new state-of-the-art laboratory, combined with the deep knowledge of our scientists, gives an advantage to clients developing novel therapeutics and diagnostic products in oncology, liver disease, and skin diseases. This convergence of trials, labs, and data sciences is driving faster clinical development and approval.

Laboratories 52

Laboratories Clinical Research Clinical Trials Cell Biology 52

The Pharma Data

JUNE 25, 2021

First-Time Disease-Free Survival Data to be Presented During Plenary Session at the 2021 ASCO Annual Meeting. 41.5), KEYTRUDA demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death by 32% compared to placebo (HR=0.68 [95% CI, 0.53–0.87]; KENILWORTH, N.J.–(BUSINESS

Disease 52

Disease Therapies Treatment Medical Schools 52

Vial

APRIL 24, 2024

Introduction In a landscape where many contract research organizations (CROs) are available, Vial is breaking through with its promise to deliver on its vision to empower scientists to cure all human diseases by reimagining clinical trials. Dermatology Phase I Units are critical to advancing care and validating treatments.

Clinical Trials 52

Clinical Trials Biosimilars Trials Disease 52

The Pharma Data

OCTOBER 1, 2021

Deucravacitinib demonstrated efficacy no matter baseline characteristics, including weight , disease severity and former treatment with biologic or non-biologic therapies. Deucravacitinib is being studied in multiple immune-mediated diseases, including psoriasis, rheumatoid arthritis , lupus and inflammatory bowel disease.

Disease 52

Disease Laboratories Clinical Pharmacology Treatment 52

PPD

NOVEMBER 30, 2023

To get a pulse on the changing industry, the PPD clinical research business of Thermo Fisher Scientific surveyed 150 biotech and biopharma leaders for the second year in a row to illuminate industry trends, challenges and sentiments. Companies that leverage innovative RWD approaches will be at the cutting edge.

Clinical Trials 98

Clinical Trials Trials Clinical Research Drug Development 98

Conversations in Drug Development Trends

JULY 29, 2024

Obesity is a major factor in the prevalence of T2D, and it is vital to develop T2D treatments with this in mind. Evolving sentiments recognize obesity as a medical condition and lifestyle choice as well as a chronic disease with genetic, psychological, cultural, and environmental causes (Figure 1).

Clinical Research 52

Clinical Research Research Clinical Trials Treatment 52

The Pharma Data

SEPTEMBER 28, 2021

10) and who haven’t received prior chemotherapy for metastatic disease. Triple-negative carcinoma grows and spreads faster than other sorts of carcinoma and consequently features a worse prognosis,” said Dr. Vicki Goodman, vice chairman , clinical research, Merck Research Laboratories. Source link: [link].

Research Laboratories 52

Research Laboratories Clinical Research Treatment Disease 52

The Pharma Data

NOVEMBER 10, 2020

P otential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease. Crohn’s Disease Therapeutics Market Size $4.7 Phase1b/2 clinical study to be conducted in the United States and several European countries. Billion by 2025. and Europe.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

PPD

MAY 11, 2023

Children and the elderly are among the most vulnerable populations and must be given special consideration in vaccine clinical trials to ensure their protection against vaccine-treatable diseases. The Many Considerations of Pediatric Vaccine Clinical Trials Childhood vaccines are highly effective in the prevention of many diseases.

Vaccine 52

Vaccine Clinical Trials Long-Term Care Facilities Trials 52

PPD

NOVEMBER 21, 2023

To keep a pulse on this rapidly changing industry, the PPD clinical research business of Thermo Fisher Scientific surveyed 150 leaders in the biopharma and biotech industries for the second consecutive year. Differences in size, resources and agility have led the two groups to take different approaches to clinical development.

Clinical Development 52

Clinical Development Clinical Trials Trials Clinical Research 52

PPD

MARCH 13, 2024

In every early phase clinical trial, the transportation, chain of custody, environmental monitoring and subsequent analysis of biological samples are the cornerstones of a successful, robust and quality outcome. Within cell therapy clinical trials, apheresis collections contribute to the specific constituents of the given therapy.

Clinical Development 98

Clinical Development Clinical Trials Therapies Laboratories 98

The Pharma Data

JANUARY 6, 2021

“Further, PDE4-inhibition is a well-documented pharmacological target for a number of other inflammatory indications, and we look forward to advancing our clinical research to realize the full potential of orismilast for the benefit of the millions of patients living with inflammatory conditions globally,” adds Professor Sommer.

FDA Approval 52

FDA Approval FDA Clinical Development Clinical Research 52

The Pharma Data

JANUARY 4, 2021

for expanding activities in the US with its initial focus on facilitating clinical development. Burr Boulevard, Teaneck, NJ 07666 (3) President: Yasushi Miyazawa (4) Scope of business: Clinical research and development (5) Paid in capital: US$100,000. (2) Location: 500 Frank W.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceuticals Clinical Development Clinical Research 40

LifeSciVC

JULY 11, 2023

Redig, SVP and Head of Clinical Development at HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC The American Cancer Society for Oncology (ASCO) annual meeting is among the highlights of the clinical oncology calendar. By Amanda J.

Therapies 67

Therapies Trials Clinical Development Science 67

Advarra

NOVEMBER 29, 2022

Bottlenecks in the manufacturing process, supply chain issues such as accessibility of good manufacturing practice (GMP)-grade reagents, and shortages of qualified scientists and engineers have caused many therapies to fail at critical stages of the clinical development pipeline. Improving Communication Between FDA and Sponsors.

Therapies 52

Therapies FDA Clinical Trials Production 52